Melanoma Archives - Medical Conferences

Neoadjuvant nivolumab/ipilimumab improves DMFS in stage III resectable melanoma

Presented By

Dr Minke Lucas, Netherlands Cancer Institute, the Netherlands

Trial

Phase 3, NADINA

Conference

ESMO 2024

Type

Peer-reviewed article

4 November 2024 12:00

New neoadjuvant combinations in stage III melanoma

Presented By

Dr Alexander Menzies, University of Sydney, Australia

Trial

Phase 1/2, KEYMAKER-U02

Conference

ESMO 2024

Type

Peer-reviewed article

4 November 2024 11:58

Long-term benefit of nivolumab, ipilimumab, and pembrolizumab: 10-year survival data

Trial

Phase 3, KEYNOTE-006, CheckMate 067

Conference

ESMO 2024

Type

Peer-reviewed article

4 November 2024 11:53

Neoadjuvant intralesional daromun improves relapse-free survival in stage III melanoma

Presented By

Prof. Axel Hauschild, Universitätsklinikum Schleswig-Holstein, Germany

Trial

Phase 3, PIVOTAL

Conference

ASCO 2024

Type

Peer-reviewed article

18 July 2024 14:13

Intratumoural tilsotolimod shows no benefit for advanced refractory melanoma

Presented By

Prof. Caroline Robert, Gustave Roussy, France

Trial

Phase 3, ILLUMINATE-301

Conference

ASCO 2024

Type

Peer-reviewed article

18 July 2024 14:09

Artificial intelligence in dermatology: current applications and future horizons

Presented By

Tobias Sangers, Leiden University Medical Center, the Netherlands

Conference

DDD 2024

Type

Peer-reviewed article

31 May 2024 13:01

Ins and outs of tumour-infiltrating lymphocytes therapy in metastatic melanoma

Presented By

Dr Tom Seijkens, Netherlands Cancer Institute, the Netherlands

Conference

DDD 2024

31 May 2024 12:40

Response-directed treatment personalisation in stage III melanoma

Presented By

Dr Irene Reijers, Netherlands Cancer Institute, the Netherlands

Trial

Phase 2, OpACIN-neo, PRADO

Conference

ASCO 2023

Type

Peer-reviewed article

2 August 2023 09:30

Prognostic and predictive biomarkers in patients with resected stage IIB/C melanoma

Presented By

Prof. Georgina Long, University of Sydney, Australia

Trial

Phase 3, CheckMate76K

Conference

ASCO 2023

Type

Peer-reviewed article

2 August 2023 09:27

The role of surgeons in stage I–II melanoma

Presented By

Dr Dirk Grünhagen, Erasmus MC, the Netherlands

Conference

DDD 2023

Type

Peer-reviewed article

10 May 2023 13:26

Melanoma: Surveillance and follow-up

Presented By

Dr Remco van Doorn, Leiden University Medical Center, the Netherlands

Conference

DDD 2023

Type

Peer-reviewed article

10 May 2023 13:19

Treatment with tumour-infiltrating lymphocytes for advanced melanoma outperforms ipilimumab

Presented By

Prof. John Haanen, Netherlands Cancer Institute, the Netherlands

Conference

ESMO 2022

Type

Peer-reviewed article

16 November 2022 18:29

Neoadjuvant pembrolizumab outperforms adjuvant pembrolizumab in resectable stage III–IV melanomas

Presented By

Dr Sapna Patel, MD Anderson Cancer Center, TX, USA

Trial

Phase 2, SWOG S1808

Conference

ESMO 2022

Type

Peer-reviewed article

16 November 2022 18:26

Survival-benefit of neoadjuvant T-VEC maintained over 5 years of follow-up

Presented By

Prof. Reinhard Dummer, University of Zürich, Switzerland

Trial

T-VEC

Conference

ESMO 2022

Type

Peer-reviewed article

16 November 2022 18:24

Baseline ctDNA predicts survival in resected stage III–IV melanoma

Presented By

Prof. Georgina Long, University of Sydney, Australia

Trial

Phase 3, CheckMate 915

Conference

ESMO 2022

Type

Peer-reviewed article

16 November 2022 18:21

Decreased overall survival in melanoma patients with low vitamin D

Presented By

Dr Inés Gracia-Darder, Son Espases University Hospital, Spain

Conference

EADV 2022

Type

Peer-reviewed article

5 November 2022 11:09

First results on distant metastasis-free survival in stage II melanoma

Presented By

Prof. Georgina Long, The University of Sydney, Australia

Trial

Phase 3, KEYNOTE-716

Conference

ASCO 2022

Type

Peer-reviewed article

5 August 2022 13:54

Higher response rates for concurrent triple therapy versus sequential therapy in melanoma

Presented By

Prof. Georgina Long, The University of Sydney, Australia

Trial

Phase 2, NeoTrio

Conference

ASCO 2022

Type

Peer-reviewed article

5 August 2022 13:50

Expanding the toolbox: what is new in melanoma detection?

Presented By

Prof. James Grichnik, University of South Florida, USA

Conference

ICD 2021

Type

News article

2 December 2021 17:21

Adjuvant immunotherapy reduces risk of disease recurrence in stage II melanoma

Presented By

Dr Jason Luke, UPMC Hillman Cancer Center, PA, USA

Trial

Phase 3, KEYNOTE-716

Conference

ESMO 2021

Type

Peer-reviewed article

19 November 2021 09:30

IFN-γ signature predicts response to immunotherapy

Presented By

Prof. Christian Blank, Netherlands Cancer Institute, the Netherlands

Trial

Phase 1, DONIMI

Conference

ESMO 2021

Type

Peer-reviewed article

19 November 2021 09:30

Updated results of SECOMBIT trial

Presented By

Prof. Paolo Ascierto, Istituto Nazionale Tumori "Fondazione Pascale", Italy

Trial

Phase 2, SECOMBIT

Conference

ESMO 2021

Type

Peer-reviewed article

19 November 2021 09:30

Combining T-VEC and pembrolizumab does not significantly improve survival in advanced, unresectable melanoma

Presented By

Dr Helen Gogas, National and Kapodistrian University of Athens, Greece

Trial

Phase 3, MASTERKEY-265

Conference

ESMO 2021

Type

Peer-reviewed article

19 November 2021 09:30

Durable intracranial responses with nivolumab/ipilimumab

Presented By

Dr Kim Margolin, City of Hope, CA, USA

Trial

Phase 2, CheckMate204

Conference

ESMO 2021

Type

Peer-reviewed article

19 November 2021 09:29

Long-term results from ground-breaking melanoma trials

Presented By

Dr Jedd Wolchok (Memorial Sloan Kettering Cancer Center, NY, USA). Prof. Reinhard Dummer (University Hospital Zürich, Switzerland) , Prof. Georgina Long (Melanoma Institute, Australia)

Trial

CheckMate 067, COLUMBUS, ABC

Conference

ASCO 2021

Type

Peer-reviewed article

12 August 2021 23:10

Novel dual checkpoint blockade improves progression-free survival in melanoma

Presented By

Dr Evan Lipson, Johns Hopkins University, MD, USA

Trial

Phase 3, RELATIVITY-047

Conference

ASCO 2021

Type

Peer-reviewed article

12 August 2021 22:14

Neoadjuvant therapy with nivolumab plus relatlimab is safe and effective in patients with stage III melanoma

Presented By

Dr Rodabe Amaria , MD Anderson Cancer Center, TX, USA

Trial

Phase 2

Conference

ASCO 2021

Type

Peer-reviewed article

12 August 2021 12:16

Adjuvant pembrolizumab: durable RFS for stage III melanoma

Presented By

Prof. Alexander Eggermont, Princess Máxima Centre, NL

Trial

Phase 3, EORTC 1325-MG/KEYNOTE-054

Conference

ASCO 2020

23 February 2021 10:00

Adjuvant pembrolizumab: durable RFS for stage III melanoma

Presented By

Prof. Alexander Eggermont, Princess Máxima Centre, NL

Trial

Phase 3, EORTC 1325-MG/KEYNOTE-054

Conference

ASCO 2020

28 August 2020 15:45

Pembrolizumab leads to higher toxicity risk in obese melanoma patients

Presented By

Ms Surya Ravichandran, Duke University, USA

Conference

AAD 2020

Type

Peer-reviewed article

6 August 2020 07:03

Can gene expression help to pick the right biologic to treat psoriasis in cancer patients?

Presented By

Dr Nikolai Klebanov , Brigham and Women’s Hospital, USA

Conference

AAD 2020

Type

Peer-reviewed article

6 August 2020 07:01

Cancer treatment with checkpoint inhibitors in RA patients?

Presented By

Dr Sabina Sandigursky, New York University Langone Medical Center, USA

Conference

ACR 2019

Type

Peer-reviewed article

4 February 2020 11:13

Long-term data from CheckMate 067

Presented By

Prof. James Larkin, Royal Marsden NHS Foundation Trust, London, UK

Trial

Phase 3, CheckMate 067

Conference

ESMO 2019

Type

Peer-reviewed article

26 November 2019 23:06

Adjuvant nivolumab provides benefit

Presented By

Prof. Jeffrey S. Weber, NYU Langone Medical Center, New York City, USA

Trial

Phase 3, CheckMate 238

Conference

ESMO 2019

Type

Peer-reviewed article

26 November 2019 22:15

Nivolumab+ipilimumab superior to monotherapy for melanoma brain metastases

Presented By

Prof. Georgina Long, Melanoma Institute Australia, Sydney, Australia

Trial

ABC

Conference

ESMO 2019

Type

Peer-reviewed article

26 November 2019 14:15

Above-the-neck melanoma more prone to metastases

Presented By

Dr Mohammed Al Abadie, Cross Hospital; Cannock Chase Hospital, United Kingdom

Conference

EADV 2019

Type

Peer-reviewed article

9 October 2019 20:53

Will malignant melanoma become a curable disease?

Presented By

Prof. Claus Garbe; Prof. Caroline Robert

Trial

COMBI-d, COMBI-v, COMBI-i, KEYNOTE-001

Conference

WCD 2019

Type

Peer-reviewed article

26 August 2019 20:46

Surgical management of melanoma

Presented By

Prof. John Kelly, The Alfred Hospital, Australia

Conference

WCD 2019

Type

Peer-reviewed article

26 August 2019 11:48

Skin toxicity of immune checkpoint inhibitors

Presented By

Prof. Jennifer N. Choi, Northwestern Feinberg School of Medicine, USA

Conference

WCD 2019

Type

Peer-reviewed article

26 August 2019 10:44

Nivolumab-mediated adverse events are independent of efficacy in resected advanced melanoma

Presented By

Prof. Mario Mandalà, Papa Giovanni XXIII Cancer Centre Hospital, Bergamo, Italy

Trial

CheckMate 238

Conference

ASCO 2019

Type

Peer-reviewed article

15 July 2019 23:18

Long term quality of life with nivolumab, or in combination (ipilimumab) in advanced melanoma

Trial

Phase 3, CheckMate 067

Conference

ASCO 2019

Type

Peer-reviewed article

15 July 2019 12:45

Melanoma incidence continues to rise in Europe

Presented By

Emily Dando, University of Pittsburgh School of Medicine, USA

Conference

AAD 2018

Type

Peer-reviewed article

20 December 2018 18:15

Lesions in paediatric patients and possible correlation with coffee drinking

Presented By

Dr Ryan Kelm, Feinberg School of Medicine, USA

Conference

AAD 2018

Type

Peer-reviewed article

20 December 2018 17:22

CNNs and targeted combination therapy

Presented By

Dr Allan Halpern, Memorial Sloan Kettering Cancer Center, USA

Conference

AAD 2018

Type

Peer-reviewed article

20 December 2018 15:27